collection
MENU ▼
Read by QxMD icon Read
search

Psoriasis

shared collection
12 papers 100 to 500 followers
https://read.qxmd.com/read/29893222/efficacy-and-safety-of-guselkumab-in-patients-with-active-psoriatic-arthritis-a-randomised-double-blind-placebo-controlled-phase-2-study
#1
RANDOMIZED CONTROLLED TRIAL
Atul Deodhar, Alice B Gottlieb, Wolf-Henning Boehncke, Bin Dong, Yuhua Wang, Yanli Zhuang, William Barchuk, Xie L Xu, Elizabeth C Hsia
BACKGROUND: Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis. Psoriatic arthritis is a common comorbidity of psoriasis with an umet need for novel treatments. We assessed the efficacy and safety of guselkumab in patients with active psoriatic arthritis. METHODS: We did a randomised, double-blind, placebo-controlled, phase 2a trial at 34 rheumatology and dermatology practices in Canada, Germany, Poland, Romania, Russia, Spain, and the USA...
June 2, 2018: Lancet
https://read.qxmd.com/read/29610923/psoriasis
#2
Mark Lebwohl
Psoriasis, an inherited disorder of the immune system, presents most commonly in the skin and joints but is also associated with cardiovascular, metabolic, and neuropsychiatric effects. Treatments include topical therapy for mild disease; phototherapy and oral therapy, such as retinoids and immunomodulating agents; and targeted biologic therapies that have revolutionized treatment of psoriasis and psoriatic arthritis. Primary care physicians should be aware of the systemic associations of psoriasis and the treatments available for this disorder...
April 3, 2018: Annals of Internal Medicine
https://read.qxmd.com/read/30499246/2018-american-college-of-rheumatology-national-psoriasis-foundation-guideline-for-the-treatment-of-psoriatic-arthritis
#3
Jasvinder A Singh, Gordon Guyatt, Alexis Ogdie, Dafna D Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M Elaine Husni, Sarah Kenny, Jennifer Kwan-Morley, Janice Lin, Paula Marchetta, Philip J Mease, Joseph F Merola, Julie Miner, Christopher T Ritchlin, Bernadette Siaton, Benjamin J Smith, Abby S Van Voorhees, Anna Helena Jonsson, Amit Aakash Shah, Nancy Sullivan, Marat Turgunbaev, Laura C Coates, Alice Gottlieb, Marina Magrey, W Benjamin Nowell, Ana-Maria Orbai, Soumya M Reddy, Jose U Scher, Evan Siegel, Michael Siegel, Jessica A Walsh, Amy S Turner, James Reston
OBJECTIVE: To develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF). METHODS: We identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review Team performed a systematic literature review to summarize evidence supporting the benefits and harms of available pharmacologic and nonpharmacologic therapies for PsA...
November 30, 2018: Arthritis & Rheumatology
https://read.qxmd.com/read/29893226/the-pathogenesis-of-psoriatic-arthritis
#4
REVIEW
Douglas J Veale, Ursula Fearon
Psoriatic arthritis is a chronic, immune-mediated, inflammatory arthropathy that presents with inflammation of the joints and entheses, including those of the axial skeleton, and is associated with increased mortality from cardiovascular disease. Diagnosis is primarily based on clinical phenotype because of the diversity of the associated features, which can include skin and nail disease, dactylitis, uveitis, and osteitis. Improved understanding of the pathogenesis of psoriatic arthritis has led to the development of effective biologics and small-molecular drugs targeting specific cytokines and signalling pathways, which can prevent disease progression and improve quality of life...
June 2, 2018: Lancet
https://read.qxmd.com/read/29146740/validation-of-the-psoriatic-arthritis-impact-of-disease-psaid-questionnaire-and-its-potential-as-a-single-item-outcome-measure-in-clinical-practice
#5
Richard Holland, William Tillett, Eleanor Korendowych, Charlotte Cavill, Nicola Waldron, Melanie Brooke, Neil J McHugh
OBJECTIVES: The Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire is a recently developed patient-reported outcome measure (PROM) of disease impact in psoriatic arthritis (PsA). We set out to assess the validity in an independent cohort of patients, estimate the minimally important difference for improvement and explore the potential of individual components of the PsAID in clinical practice. METHODS: Data were collected prospectively for a single-centre cohort of patients with PsA...
March 2018: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/28722163/risk-of-cancer-in-patients-with-psoriasis-on-biological-therapies-a-systematic-review
#6
REVIEW
E Peleva, L S Exton, K Kelley, C E Kleyn, K J Mason, C H Smith
BACKGROUND: Biological therapies are highly effective in psoriasis, but have profound effects on innate and adaptive immune pathways that may negatively impact on cancer immunosurveillance mechanisms. OBJECTIVES: To investigate the risk of cancer in patients with psoriasis treated with biological therapy. METHODS: We searched MEDLINE, Embase, and the Cochrane Library (up to August 2016) for randomized controlled trials, prospective cohort studies and systematic reviews that reported cancer incidence in people exposed to biological therapy for psoriasis compared with a control population...
January 2018: British Journal of Dermatology
https://read.qxmd.com/read/23769296/efficacy-and-safety-of-ustekinumab-in-patients-with-active-psoriatic-arthritis-1-year-results-of-the-phase-3-multicentre-double-blind-placebo-controlled-psummit-1-trial
#7
RANDOMIZED CONTROLLED TRIAL
Iain B McInnes, Arthur Kavanaugh, Alice B Gottlieb, Lluís Puig, Proton Rahman, Christopher Ritchlin, Carrie Brodmerkel, Shu Li, Yuhua Wang, Alan M Mendelsohn, Mittie K Doyle
BACKGROUND: Many patients with psoriasis develop psoriatic arthritis, a chronic inflammatory disease that afflicts peripheral synovial, axial, and entheseal structures. The fully human monoclonal antibody ustekinumab is an efficacious treatment for moderate-to-severe plaque psoriasis. We did a randomised, placebo-controlled, phase 3 trial to assess the safety and efficacy of ustekinumab in patients with active psoriatic arthritis. METHODS: In this phase 3, multicentre, double-blind, placebo-controlled trial at 104 sites in Europe, North America, and Asia-Pacific, adults with active psoriatic arthritis (≥5 tender and ≥5 swollen joints, C-reactive protein ≥3·0 mg/L) were randomly assigned (1:1:1, by dynamic central randomisation based on an algorithm implemented by an interactive voice-web response system) to 45 mg ustekinumab, 90 mg ustekinumab, or placebo at week 0, week 4, and every 12 weeks thereafter...
August 31, 2013: Lancet
https://read.qxmd.com/read/24940651/killing-two-birds-with-one-stone-oral-tofacitinib-reverses-alopecia-universalis-in-a-patient-with-plaque-psoriasis
#8
LETTER
Brittany G Craiglow, Brett A King
No abstract text is available yet for this article.
December 2014: Journal of Investigative Dermatology
https://read.qxmd.com/read/25313095/safety-and-efficacy-of-brodalumab-for-psoriasis-after-120-weeks-of-treatment
#9
Kim Papp, Craig Leonardi, Alan Menter, Elizabeth H Z Thompson, Cassandra E Milmont, Greg Kricorian, Ajay Nirula, Paul Klekotka
BACKGROUND: Brodalumab (anti-interleukin-17-receptor antibody) was effective in treating moderate to severe psoriasis in a 12-week, dose-ranging, placebo-controlled trial. OBJECTIVE: We sought to evaluate efficacy and safety of long-term brodalumab treatment. METHODS: In this interim analysis at week 120 of an open-label extension study, patients received brodalumab 210 mg every 2 weeks. Protocol amendments reduced the dose (140 mg) in patients weighing 100 kg or less and subsequently increased the dose (210 mg) in patients with inadequate responses...
December 2014: Journal of the American Academy of Dermatology
https://read.qxmd.com/read/24441097/transcriptome-analysis-of-psoriasis-in-a-large-case-control-sample-rna-seq-provides-insights-into-disease-mechanisms
#10
Bingshan Li, Lam C Tsoi, William R Swindell, Johann E Gudjonsson, Trilokraj Tejasvi, Andrew Johnston, Jun Ding, Philip E Stuart, Xianying Xing, James J Kochkodan, John J Voorhees, Hyun M Kang, Rajan P Nair, Goncalo R Abecasis, James T Elder
To increase our understanding of psoriasis, we used high-throughput complementary DNA sequencing (RNA-seq) to assay the transcriptomes of lesional psoriatic and normal skin. We sequenced polyadenylated RNA-derived complementary DNAs from 92 psoriatic and 82 normal punch biopsies, generating an average of ∼38 million single-end 80-bp reads per sample. Comparison of 42 samples examined by both RNA-seq and microarray revealed marked differences in sensitivity, with transcripts identified only by RNA-seq having much lower expression than those also identified by microarray...
July 2014: Journal of Investigative Dermatology
https://read.qxmd.com/read/23677316/do-tnf-inhibitors-reduce-the-risk-of-myocardial-infarction-in-psoriasis-patients
#11
April W Armstrong
OBJECTIVE: To assess whether patients with psoriasis treated with tumor necrosis factor (TNF) inhibitors have a decreased risk of myocardial infarction (MI) compared with those not treated with TNF inhibitors. DESIGN: Retrospective cohort study. SETTING: Kaiser Permanente Southern California health plan. PATIENTS: Patients with at least 3 International Classification of Diseases, Ninth Revision, Clinical Modification, codes for psoriasis (696...
May 15, 2013: JAMA: the Journal of the American Medical Association
https://read.qxmd.com/read/24942203/comorbidities-and-health-related-quality-of-life-in-spanish-patients-with-moderate-to-severe-psoriasis-a-cross-sectional-study-arizona-study
#12
MULTICENTER STUDY
Jose Luis Sanchez-Carazo, Jose Luis López-Estebaranz, Cristina Guisado
Psoriasis is a common, chronic inflammatory immunologically mediated disease of the skin, showing a high prevalence of associated comorbidities, and strongly affecting patients' health-related quality of life (HR-QOL), with profound impact on the psychological aspect. We aimed to establish the correlation between HR-QOL and the associated comorbidities in patients with moderate to severe psoriasis in Spain. A cross-sectional, observational, epidemiological study was conducted at 68 dermatology-based centers across Spain...
August 2014: Journal of Dermatology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"